Versartis Reports Third Quarter 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Versartis Reports Third Quarter 2015 Financial Results

MENLO PARK, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ: VSAR ), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial results for the third quarter and nine months ended September 30, 2015.

Jay Shepard, Chief Executive Officer, commented, "With the initiation of VITAL, our Phase 2 trial for once-monthly treatment in adult GHD patients, we added another significant market opportunity for somavaratan during the quarter. We believe there is significant need for a long-acting treatment in this adult population. With three late-stage trials and our ongoing Extension Study, Versartis is continuing to make important advancements in the clinical development of somavaratan and is positioning the company for long-term growth within very attractive markets."

Mr. Shepard continued, "As we entered the fourth quarter, we continued to make good progress enrolling children into our ongoing pediatric studies and remain on track to complete enrollment of VELOCITY by the middle of 2016. Looking ahead into 2016, we have a clear focus on the development of somavaratan for both pediatric and adult patients across several geographies. To date, we have generated promising efficacy and safety results that we believe position somavaratan as the leader among current long-acting growth hormone therapies in development."

Recent Corporate Highlights & Milestones

  • Initiated VITAL Phase 2 trial of once-monthly somavaratan in adults with GHD.  
  • Presented confirmatory 18-month data at the Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) from the ongoing somavaratan Extension Study indicating that increasing the dose to 3.5mg/kg, the dose used in the VELOCITY Phase 3 trial, provided stable second-year growth rates and an adverse event profile comparable to daily treatment.  
  • Appointed Lars Ekman, MD, PhD, as Global Development Advisor, adding significant experience to the clinical development process.  
  • Announced removal of FDA partial clinical hold and continuation of somavaratan VELOCITY Phase 3 trial.

Anticipated Milestones and Other Key Events

  • Completion of VELOCITY enrollment by mid-2016.  
  • Top line data on VELOCITY's primary endpoint, 12-month height velocity, by mid-2017, potentially enabling a Biologics License Application (BLA) submission, followed by potential FDA approval by late-2018.  
  • Top line data on VITAL, our Phase 2 trial in AGHD, in Q3 2016.

Third Quarter 2015 Financial Results

For the third quarter ended September 30, 2015, Versartis reported a net loss attributable to common stockholders of approximately $20.4 million, or $0.69 per share, basic and diluted, compared to a net loss attributable to common stockholders for the quarter ended September 30, 2014 of $13.8 million, or $0.57 per share, basic and diluted.

Total operating expenses for the quarter ended September 30, 2015 were $20.5 million compared to $14.1 million for the quarter ended September 30, 2014. Research and development (R&D) expenses for the quarter ended September 30, 2015 were $15.4 million, compared to $10.5 million for the quarter ended September 30, 2014. The increase in R&D expenses was primarily due to site initiation and start-up activities related to the Company's Phase 2 and Phase 3 clinical trials, including the VITAL Phase 2 trial for adults, the VELOCITY global Phase 3 trial and the Phase 2/3 trial of somavaratan in pediatric patients in Japan. General and administrative (G&A) expenses were $5.1 million for the quarter ended September 30, 2015, compared to $3.6 million for the quarter ended September 30, 2014. The increase in G&A expenses was primarily due to the additional fees related to consulting and professional services to support our growth and expansion of our infrastructure.

Total operating expenses for the nine months ended September 30, 2015 were $62.3 million compared to $30.2 million for the nine months ended September 30, 2014. R&D expenses for the nine months ended September 30, 2015 were $44.4 million, compared with $21.0 million for the nine months ended September 30, 2014. The increase in R&D expenses was primarily due to manufacturing and clinical start-up activities related to the Company's Phase 2 and Phase 3 clinical trials, including the VITAL Phase 2 trial for adults, the VELOCITY global Phase 3 trial and the Phase 2/3 trial of somavaratan in pediatric patients in Japan. General and administrative (G&A) expenses were $17.9 million for the nine months ended September 30, 2015, compared to $9.2 million for the nine months ended September 30, 2014. The increase in G&A expenses was primarily due to the additional fees related to consulting and professional services, the one-time non-recurring expenses of $2.4 million associated with our CEO transition that occurred in the second quarter of 2015, as well as an increase in headcount.

Total operating expenses for the quarter ended September 30, 2015 include non-cash stock-based compensation expense of $2.3 million, compared to $1.6 million of non-cash stock-based compensation expense for the quarter ended September 30, 2014. For the nine months ended September 30, 2015, operating expenses include $8.5 million of non-cash stock-based compensation expense, including a one-time non-recurring charge of $2.0 million associated with our CEO transition, compared to $3.0 million for the nine months ended September 30, 2014.

Cash and cash equivalents were $198.0 million as of September 30, 2015.

About Versartis, Inc.

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone for the treatment of growth hormone deficiency (GHD). Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. The Company completed the Phase 2a stage of a Phase 1b/2a trial evaluating weekly, twice-monthly and monthly dosing regimens of somavaratan in children with GHD in June 2014 and initiated a global Phase 3 registration trial, VELOCITY, in GHD children in January 2015. In addition, the Company initiated a Phase 2/3 trial in Japan for children with GHD in April 2015 and a Phase 2 trial, VITAL, evaluating once-monthly dosing for adults with GHD in September 2015. Additional information on Versartis clinical trials can be found at www.versartistrials.com . Further information on Versartis can be found at  www.versartis.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our success being heavily dependent on somavaratan; somavaratan being a new chemical entity; the risk that somavaratan may not have favorable results in clinical trials or receive regulatory approval; potential delays in our clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients; the risk that somavaratan may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that we may encounter difficulties in manufacturing somavaratan; if somavaratan is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing our intellectual property rights; our reliance on our license of intellectual property from Amunix Operating, Inc. and our need for additional funds to support our operations. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2014, and in our Quarterly Report on Form 10-Q for the three months ended June 30, 2015, which are on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Versartis, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share amounts)
         
  Three Months Ended Nine Months Ended
  September 30, September 30,
  2015 2014 2015 2014
Operating expenses        
Research and development $15,400 $10,515 $44,440 $21,006
General and administrative 5,124 3,577 17,861 9,167
Total operating expenses 20,524 14,092 62,301 30,173
Loss from operations (20,524) (14,092) (62,301) (30,173)
Interest income 54 50 168 89
Other income (expense), net 91 208 81 (11,776)
Net loss and comprehensive loss (20,379) (13,834) (62,052) (41,860)
Deemed dividend related to beneficial conversion feature of convertible preferred stock — — — (25,559)
Net loss attributable to common stockholders $(20,379) $(13,834) $(62,052) $(67,419)
Net loss per basic and diluted share attributable to common stockholders $(0.69) $(0.57) $(2.15) $(3.93)
Weighted-average common shares used to compute basic and diluted net loss per share 29,354 24,195 28,825 17,138
         
         
Versartis, Inc.        
Condensed Consolidated Balance Sheets        
(Unaudited)        
(In thousands)        
         
      September 30, December 31,
      2015 2014
Assets:        
Cash and cash equivalents     $198,014 $170,566
Other assets     3,550 3,728
Total assets     $201,564 $174,294
Liabilities and stockholders' equity:        
Liabilities     $7,388 $6,925
Total stockholders' equity     194,176 167,369
Total liabilities and stockholders' equity     $201,564 $174,294

Corporate & Investors: Joshua Brumm Chief Financial Officer (650) 963-8582 Investors: Nick Laudico/David Burke The Ruth Group (646) 536-7030/7009 Media: Debra Bannister Corporate Communications (530) 676-7373

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 89

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 97

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
UnitedHealth’s CMS Audit Shock Puts Disclosures Under Lens

Updated Category News Views 62

Medicare Advantage's audit bill just landed with a nasty thud. UnitedHealth Group shares fell more than 10% on November 18 after the Centers for Medicare & Medicaid Services proposed new anti-fraud, audit, and repayment rules for the program. For holders of NYSE:UNH, this was not some sleepy policy memo buried in a federal filing cabinet. It was a hard reminder that...

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 20

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 112

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 22

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 87

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 102

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 93

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Surge in Panic Attack Treatment Market Anticipated

Updated Category News Views 140

Overview of the Panic Attack Treatment Market The panic attack treatment market is on a remarkable trajectory, anticipated to grow significantly in the coming years. The global market value is expected to soar from USD 2.92 billion to USD 8.66 billion, averaging a compound annual growth rate (CAGR) of 16.8%. This growth reflects a broader understanding and acceptance of...

Continue Reading
YipitData Enhances Global Insights in Europe and China

Updated Category News Views 196

YipitData Expands Global Insights YipitData, a prominent provider of alternative data, has announced its significant expansion into the European and Chinese markets. This exciting development follows the company's dedication to serving over 500 investors, facilitating deep insights into brand performance that influence market strategies. With the launch of new products...

Continue Reading
Silver Viper Minerals Makes Strategic Move to Acquire Coneto Project

Updated Category News Views 224

Silver Viper Minerals Announces Acquisition of Coneto Project Silver Viper Minerals Corp. has recently reached a binding agreement to acquire the Coneto Silver-Gold Project. This acquisition marks a significant milestone in the company's growth strategy, enabling it to expand its interests in the precious metals landscape of Mexico. Details of the Acquisition The...

Continue Reading
Vendasta Celebrated for Its Innovative Corporate Culture

Updated Category News Views 130

Vendasta Honored as a Top Corporate Culture in Canada Vendasta, a pioneering force in artificial intelligence solutions, has recently received commendation as one of Canada’s Most Admired Corporate Cultures. This recognition highlights the extraordinary environments that companies cultivate, significantly impacting their overall success. The award, given by Waterstone...

Continue Reading
Nordic Capital Exits ArisGlobal; Dassault Systèmes Wins

Updated Category News Views 22

Strategic Sale: Nordic Capital Exits with ArisGlobal Sometimes in this market, ya gotta hand the reins over after running a long game, and that's what Nordic Capital's doing with ArisGlobal. After investing heavily to turn ArisGlobal into an AI-enabled juggernaut in the life sciences sector, Nordic's calling it a day and selling the whole package to Dassault Systèmes. I...

Continue Reading